On Friday, the Vetr crowd upgraded their rating for Alnylam Pharmaceuticals, Inc.ALNY from its previous position at 1 star (Strong Sell) issued 88 days ago, to 4.5 star (Strong Buy). Crowd sentiment for the stock is edging positive with 66 percent of Vetr user ratings bullish.
The massive upgrade for Alnylam arrives on the same day the company announced it would livestream its R&D day press conference to investors. At the recent American Society of Hematology meeting in San Diego, the company revealed positive results in early tests of fitusiran, an experimental drug used to treat the effects of hemophilia.
Share price in Anylam enjoyed a healthy 6.6 percent jump early in the trading day on December 9. By 2 p.m. that same day, the stock had settled at $42.25.
See how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for the stock is up at $49.75, which is still far below the average analyst price of $70.13. Less than 2 percent of Vetr users are holding ALNY in their watch-lists.
At last check, Alnylam shares were up 3.54 percent at $42.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
